Ferric ion Inhibitors
1 drugsAbout Ferric ion
The ferric ion (Fe3+) is an essential element involved in biological processes, making its availability crucial for maintaining health. Dysregulation of iron homeostasis can contribute to various conditions, highlighting its importance in the body.
Targeting ferric ions is of interest due to its role in oxygen transport, enzyme function, and DNA synthesis. However, there is currently no genetic evidence directly linking ferric ion levels to specific diseases.
DEFERIPRONE is the only FDA-approved drug targeting ferric ions, developed by SENORES PHARMS and approved in 2019. It is a small molecule used in an 'other' therapeutic area.
Top Ferric ion Drugs
SENORES PHARMS is the only company with an approved drug targeting ferric ions.
Low competition suggests high entry barriers or limited market potential for this target.
Ferric ion Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Ferric ion, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches.
Ferric ion Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Ferric ion. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 | 100% |
| Phase 2 | 16 | 12 | 1 | 3 | 92% |
| Phase 3 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 5 | 3 | 2 | 0 | 60% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Ferric ion Drug Approval Timeline (2019 - 2019)
DEFERIPRONE was both the first and most recently approved drug in 2019.
The single approval indicates a potentially unsaturated market with room for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 15 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Ferric ion. A trial counts if an approved drug acting on Ferric ion is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.